SCHEMBL3087753

SCHEMBL3087753

CCN(C(=O)C(Cc1ccc(OC)c(N)c1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LARS1 Q9P2J5 1/20 0.43
ALDH1A1 P00352 3/20 0.41
KMT2A Q03164 3/20 0.41
KDM4E B2RXH2 1/20 0.41
MMP1 P03956 2/20 0.41
MMP9 P14780 2/20 0.41
MMP13 P45452 2/20 0.41
ADAM17 P78536 1/20 0.41
F2 P00734 2/20 0.40
RAPGEF3 O95398 1/20 0.40
KAT6A Q92794 2/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 2/20 0.39
NPC1 O15118 1/20 0.39
MITF O75030 1/20 0.39
RAB9A P51151 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
MMP2 P08253 1/20 0.39
MMP8 P22894 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3091842 0.93 LARS1 (0.43) LARS1ALDH1A1KMT2AKDM4EMMP1
SCHEMBL3097161 0.92 PDE4D (0.46) LARS1ALDH1A1KMT2AKDM4EMMP1
SCHEMBL3092380 0.89 LARS1 (0.46) LARS1ALDH1A1KMT2AKDM4EF2
SCHEMBL3100322 0.88 KDM4E (0.49) LARS1ALDH1A1KMT2AKDM4EMMP1
SCHEMBL3089238 0.88 ALDH1A1 (0.43) LARS1ALDH1A1KMT2AMMP1MMP9
SCHEMBL3100750 0.87 LARS1 (0.48) LARS1ALDH1A1F2
SCHEMBL3085743 0.86 RAPGEF3 (0.42) LARS1ALDH1A1KMT2AKDM4EMMP1
SCHEMBL3097466 0.85 KDM4E (0.47) LARS1ALDH1A1KMT2AKDM4EMMP1
SCHEMBL3092629 0.84 POLB (0.55) LARS1ALDH1A1KMT2AKDM4EF2
SCHEMBL3086151 0.83 SLC16A3 (0.47) LARS1F2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 LARS1 1976/4885ALDH1A1 617/4885KMT2A 1948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.